Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

Core Insights - Terns Pharmaceuticals is advancing its clinical programs, particularly TERN-701 for chronic myeloid leukemia (CML) and TERN-601 for obesity, with significant data expected in the coming years [1][2][3] TERN-701 Updates - The Phase 1 CARDINAL study for TERN-701 has completed dose escalation as of January 2025, with dose expansion expected to begin in Q2 2025 [3] - New data indicates TERN-701 has a superior drug-drug interaction (DDI) profile compared to asciminib, allowing safer co-administration with commonly prescribed medications [2][3] - Encouraging early data from the CARDINAL trial shows compelling molecular responses in heavily pre-treated patients [3][6] TERN-601 Updates - The design for the Phase 2 FALCON study of TERN-601 is set to initiate in early Q2 2025, with 12-week data anticipated in the second half of 2025 [1][6] - The trial will evaluate the efficacy and safety of TERN-601 in adults with overweight or obesity, featuring a unique titration schedule aimed at achieving competitive weight loss without complex dosing [6][4] - TERN-601 aims to demonstrate best-in-class tolerability and weight loss outcomes compared to existing GLP-1 receptor agonists [2][6] Financial Position - As of September 30, 2024, Terns reported a cash balance of $372.8 million, which is expected to sustain operations into 2028 [4] Upcoming Events - Terns management will present at the TD Cowen 45 Annual Healthcare Conference from March 3-5, 2025, in Boston [7]